Seeking Alpha

Appeals court says Hanmi product does not infringe Nexium patent

  • A U.S. court of appeals has affirmed a district court's ruling that Hanmi has not infringed AstraZeneca's (AZN) '504 patent.
  • The court determined that "the written description limits 'alkaline salt' in the '504 patent to certain specifically named salts."
  • Ultimately, this means the district court's ruling of noninfringement is upheld.
  • AZN "respectfully disagrees" and will consider a "further appeal," Reuters notes.
  • Full decision
Comments (1)
  • mikegy
    , contributor
    Comments (2) | Send Message
    Would be nice to have a cheaper alternative to daily Nexium.
    19 Dec 2013, 09:13 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector